April 2021: Classical Hodgkin Lymphoma - Pathology and Biology

Speaker

Eric Hsi, MD
Wake Forest Baptist Health

Classical Hodgkin Lymphoma - Pathology and Biology

Dr. Hsi will review the pathologic features of classic Hodgkin lymphoma, discuss differential diagnostic considerations, and review recent advances in our understanding of the biology of Hodgkin lymphoma with an emphasis on molecular genetic and micrcoenvironmental features.

Learning objectives

  • Describe the pathologic features of Hodgkin lymphoma.
  • List entities in the differential diagnosis of Hodgkin lymphoma.
  • Describe common genetic abnormalities in Hodgkin lymphoma.

Watch the Webinar


Answers to Questions from Live Webinar

Please click here for list of questions received from the live webinar attendees.

Answers to Questions from Live Webinar

Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.

NEW QUESTION/ANSWER

It is common to see necrosis in cHL, hard to put a number on it offhand.

NEW QUESTION/ANSWER

Classic in the 2017 WHO

NEW QUESTION/ANSWER

It can be expressed in both CHL and ALCL so it may not be reliable.

NEW QUESTION/ANSWER

CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.

NEW QUESTION/ANSWER

I have never seen this.

NEW QUESTION/ANSWER

No, there is no clinical role for this at present.

NEW QUESTION/ANSWER

This would be highly unusual

NEW QUESTION/ANSWER

I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661

NEW QUESTION/ANSWER

I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH

NEW QUESTION/ANSWER

No

NEW QUESTION/ANSWER

I don’t find it that helpful

NEW QUESTION/ANSWER

There has been some data to suggest it is prognostic.

NEW QUESTION/ANSWER

It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.

NEW QUESTION/ANSWER

Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.